159 results about "Diabetic nephropathy" patented technology

The invention relates to the field of medical information processing and traditional Chinese medicine curative effect evaluation, in particular to a diabetic nephropathy traditional Chinese medicine curative effect evaluation method based on patient report outcome. The method comprises the following steps: searching related symptoms and clinical characterization data of diabetic nephropathy through a medical database, extracting target entries, performing language standardization processing, constructing an initial candidate entry set, calculating the occurrence frequency of each symptom entry, and screening entries meeting a set threshold value to form an entry set; carrying out dimension division on the entry set according to feature attributes to form a preliminary dimension structure set; forming a screening result set through preset logic screening conditions; and carrying out weighted regression fusion on the comprehensive curative effect score and clinical detection data, and outputting a patient curative effect index. In an item weight determination process, dynamic balance between subjective experience and objective statistical information is realized through a mixed weighting model, and the defects of strong subjectivity of expert scoring and large result fluctuation in a traditional method are overcome.

A class of compounds and the use thereof in a drug. Specifically, the present invention relates to a class of new compounds, a pharmaceutical composition containing the compounds, a method for preparing the compounds, and the use of the compounds or the pharmaceutical composition in the preparation of a drug for treating GLP-1 receptor agonist-mediated diseases and / or disorders, particularly the use in the preparation of a drug for treating diabetes, non-alcoholic fatty liver disease, obesity, myocardial infarction, heart failure, diabetic nephropathy, Parkinson's disease and Alzheimer's disease.

The invention provides a diabetic nephropathy early warning method, system, equipment and medium, and relates to the technical field of medical data analysis and prediction.The method comprises the steps that multiple urine samples of a user are collected, target urine protein detection is conducted, and multiple urine protein concentrations are obtained; each urine protein concentration is combined with a normal urine protein concentration set to be input into an abnormal data recognition tree, the number of layers of multiple recognition nodes is obtained, and the detection confidence coefficient is obtained through calculation; configuring an abnormal proportion according to the detection confidence coefficient, inputting a plurality of urine protein concentration combination normal urine protein concentration sets into an abnormal data identification tree, deleting urine protein concentrations divided into abnormal data in the abnormal proportion before, and obtaining screened urine protein concentrations; according to the screened urine protein concentration, an auxiliary early warning coefficient is obtained through calculation, and early warning is carried out. The technical problem of low early warning accuracy of diabetic nephropathy in the prior art is solved.

The invention provides a traditional Chinese medicine composition for treating diabetic nephropathy and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition provided by the invention is prepared from the following raw materials in parts by weight: 30 to 120 parts of raw radix astragali seu hedysari, 10 to 20 parts of radix pseudostellariae, 5 to 15 parts of herba dendrobii, 5 to 15 parts of radix trichosanthis, 10 to 20 parts of radix rehmanniae recen, 10 to 20 parts of raw radix puerariae, 25 to 35 parts of herba agrimoniae, 5 to 15 parts of rhizoma discoreae, 10 to 20 parts of fructus corni, 10 to 20 parts of ramuli euonymi, 10 to 20 parts of serissa serissoide, 25 to 35 parts of chinaroot greenbrier, 4 to 8 parts of fructus schisandrae chinensis, 10 to 20 parts of herba pyrolae and 10 to 20 parts of corn stigma. The traditional Chinese medicine composition disclosed by the invention can be used for improving the clinical curative effect, improving symptoms, repairing podocyte damage and relieving oxidative stress by virtue of unique traditional Chinese medicine composition and aiming at pathogenesis treatment of the DN with the syndrome of deficiency of both qi and yin, and a new thought and a new method are provided for traditional Chinese medicine treatment of the DN.

The invention belongs to the technical field of medicines, and particularly relates to application of BMP9 as an intervention target in preparation of a medicine for treating diabetic nephropathy. More specifically, the invention provides application of a BMP9 accelerant in preparation of a medicine for preventing and / or treating diabetic nephropathy. The BMP9 accelerant is a substance shown in the following (i) or (ii): (i) a substance for increasing the content of BMP9 in a subject; (ii) a substance that increases BMP9 activity in a subject. According to the invention, a DKD mouse model is constructed, and liver RNA-seq sequencing is carried out, such that a differential expression gene BMP9 exists between a normal mouse and a DKD mouse. It is found that BMP9 can be used as a new target for prevention and treatment of DKD and has important theoretical significance and potential clinical application value.

The invention discloses a rapid detection device for diabetic nephropathy patients, and belongs to the technical field of diabetic nephropathy patient detection.The rapid detection device comprises a blood glucose detection assembly, a self-adaptive adjusting mechanism, an extrusion force adjusting structure and an automatic blood taking mechanism, and the self-adaptive adjusting mechanism is arranged on the blood glucose detection assembly; the extrusion force adjusting structure is arranged in the blood glucose detection assembly, the extrusion force adjusting structure is connected with the self-adaptive adjusting mechanism, the extrusion force adjusting structure comprises an adjusting assembly and a reciprocating displacement assembly, and the automatic blood taking mechanism is arranged on the blood glucose detection assembly. By arranging the self-adaptive adjusting mechanism, the extrusion force adjusting structure and the automatic blood taking structure, the extrusion force for assisting the blood taking structure of the person to be detected is self-adaptively adjusted according to different thicknesses of the hands of the person to be detected, and it is ensured that the device can take out sufficient blood for detection; and tissue fluid groups which influence a detection result can be prevented from existing in blood, so that the detection precision of the device is improved.

The invention relates to the technical field of medical artificial intelligence diagnosis, and discloses a diabetic nephropathy auxiliary identification method based on multi-source data. The method comprises the following steps: starting a medical data traceability process, capturing original indexes from a multi-heterogeneous system, and arranging the original indexes into an initial data set; and performing hierarchical data fusion according to the pathological evolution knowledge graph to generate a fusion health record with a timestamp. And introducing a dynamic feature weaving process, and extracting a multi-level abnormal feature network from the physiological parameter trajectory according to the priority of the biomarker. And importing the abnormal feature network into a progressive mode learning process, training an identification engine for mapping feature combinations to different disease risk levels, and outputting an identification conclusion by the engine. According to the method, the structured abnormal mode network is constructed through priority-driven dynamic feature weaving, and the recognition engine is trained by using a progressive learning mechanism, so that the accuracy and clinical interpretability of risk stratification of diabetic nephropathy are improved.

The invention relates to the technical field of biological medicine, and discloses an application of an Aspisin small-molecule inhibitor in preparation of a medicine for preventing and / or treating diabetic nephropathy, and the Aspisin small-molecule inhibitor comprises ganoderic acid DM. The inhibitor ganoderic acid DM targeting Aspisin is screened from a bioactive compound library by combining high-throughput virtual drug screening with biological activity screening, it is found that ganoderic acid DM can be specifically combined with Aspisin and shows high affinity, and it is expected that an experimental basis is provided for clinical treatment and prevention of DKD and new drug research and development.

The invention relates to a non-invasive diabetic nephropathy grading and predicting method supporting convenient screening, which comprises the following steps: acquiring and preprocessing a color fundus image and non-invasive clinical features of a diabetic patient to obtain a multi-modal data set, and setting marks of various severity degrees of diabetic nephropathy; constructing a deep learning model A1, and obtaining diabetic nephropathy severity prediction probability distribution # imgabs0 # based on the color fundus image according to the multi-modal data set; a deep learning model A2 is constructed, and diabetic nephropathy severity prediction probability distribution # imgabs1 # based on clinical data is obtained according to the multi-modal data set; and constructing a fusion model, fusing the obtained diabetic nephropathy prediction probabilities by the fusion model through a self-adaptive weight distribution algorithm, dynamically adjusting the weight according to the prediction result output by each model, calculating a comprehensive diabetic nephropathy severity score, and outputting a final diabetic nephropathy prediction grading result according to the score.

The invention relates to the technical field of molecular biology, in particular to a methylation marker for diagnosis of diabetic nephropathy. Specifically, the methylation marker comprises a P site of a CAT gene promoter region and / or an E site of a CAT gene exon 1 region. Based on a detection system combining methylation sensitive restriction enzyme with quantitative PCR, the kit has the advantages of simplicity and convenience in operation, good repeatability, accuracy in quantification and easiness in standardization, and is suitable for low-invasive samples such as peripheral blood. By effectively distinguishing pure type 2 diabetes patients from diabetic nephropathy combined patients, a reliable technical means is provided for risk stratification, early intervention and dynamic monitoring of diabetic people, and the method has good clinical application prospects and popularization value.

The present invention relates to a pyridine polycyclic compound inhibitor, a preparation method therefor and a use thereof. In particular, the present invention relates to a compound represented by formula (I), a preparation method therefor, a pharmaceutical composition comprising the compound, and a use of the compound in a medication for treating chronic kidney disease, kidney or cardiac fibrosis, diabetic nephropathy, congestive heart failure, hypertension, primary aldosteronism, and Cushing syndrome, wherein the definitions of the substituents in formula (I) are the same as those in the description.

The invention discloses a biomarker, application of the biomarker in predicting the risk of diabetic nephropathy and a kit, which can realize non-invasive efficient evaluation on the severity of diabetic nephropathy and provide important supplement for early diagnosis and refined risk stratification of diabetic nephropathy. The ratio of the Sulfatase-1 to the creatinine Cr is uSULF1 / Cr, and the Sulfatase-1 and the creatinine Cr are both from urine.

The present disclosure relates to peptide fragments derived from interleukin-4 (IL-4) for the treatment of diabetic nephropathy.

The invention discloses core components, targets and action mechanisms of Zhibai Dihuang pills / decoction for treating early diabetic nephropathy based on a directed PPI network and a plurality of network centrality algorithms. Core components and targets of the Zhibai rehmannia pill / decoction for treating diabetic nephropathy are determined through the steps of screening active components of the Zhibai rehmannia pill / decoction, collecting target information corresponding to the active components, collecting disease related targets, obtaining drug-disease intersection genes, constructing a directed protein interaction network and the like. The action mechanism of the Zhibai rehmannia pill / decoction for treating diabetic nephropathy is researched. The invention provides a scientific theoretical basis for the treatment of diabetic nephropathy by the Zhibai Dihuang pill / decoction, and provides a new method for the clinical treatment and scientific research of the Zhibai Dihuang pill / decoction on diabetic nephropathy.

This invention relates to double-stranded oligonucleotides complementary to JAK1 that result in the regulation of JAK1 expression. Regulation of JAK1 expression is beneficial for a range of medical disorders, including inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), dry eye disease, cancer, myelofibrosis, and asthma. The invention also includes compositions comprising double-stranded oligonucleotides and therapeutic methods using double-stranded oligonucleotides.

The application discloses a kind of based on multi-source medical text construction traditional Chinese medicine diabetic nephropathy knowledge graph method and system, including following module: data integration module: integration diagnosis and treatment guideline and electronic medical record, after redundancy, terminology standardization constructs unified medical data set;Mixed labeling and entity recognition module: fusion artificial labeling and BERT-BiLSTM-CRF model automatically identifies traditional Chinese medical syndrome, traditional Chinese medicine and other complex entities;Relationship modeling module is based on semantic embedding and multi-label classification algorithm, accurately constructs traditional Chinese and western medicine association rules;Atlas application module: entity relationship is converted into attribute graph structure, supports graph database interactive query, realizes diagnosis and treatment recommendation, contraindication early warning and curative effect analysis.Through the above scheme, the present application significantly improves the accuracy of differentiation, reduces the risk of drug contraindication, provides efficient, interpretable decision support for the prevention and treatment of diabetic nephropathy, has important clinical value and popularization potential.

Disclosed herein is a deuterated compound of Formulas (I) and (II) as an FTO inhibitor with improved pharmacokinetic properties with comparable selective FTO inhibition. Also disclosed herein is a pharmaceutical composition comprising the same, and a method of inhibiting weight gain, promoting weight loss, reducing serum LDL, cholesterol, LDL-c, or triglycerides, or treating obesity or an obesity-related disease (esp. obesity-related diabetes, hyperglycemia, diabetic nephropathy, hyperlipemia, coronary heart disease, atherosclerosis, hypertension, cardiovascular or cerebrovascular disease) or Alzheimer's disease by inhibiting FTO by using the compound disclosed herein.

Methods of treating diseases and disorders treatable by AMPK activation with sephin1 and related compounds, for example metabolic syndrome, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis (NASH), obesity, type 2 diabetes, insulin resistance, glucose intolerance, chronic pain, sarcopenia, a neuromuscular disorder, heart failure, cardiac hypertrophy, diabetic cardiomyopathy, cardiac reperfusion injury, chronic kidney disease, polycystic kidney disease, diabetic nephropathy, cardiovascular diseases, inflammatory bowel disease, arthritis, hypertension, peripheral vascular disease, nephrogenic diabetes insipidus, glaucoma, an eye disease or disorder, ocular neovascularization, β-hemoglobinopathy, cancer, fibrosis, cancer cachexia, and mitochondrial disease.

The invention discloses a tricyclic compound as well as a preparation method and application thereof. In particular, the present invention relates to a compound represented by general formula (I), a preparation method thereof, a pharmaceutical composition containing the compound, and uses of the compound in drugs for treating chronic kidney disease, renal or cardiac fibrosis, diabetic nephropathy, congestive heart failure, hypertension, primary aldosteronism and Cushing's syndrome, wherein each substituent in the general formula (I) is as defined in the specification.

The invention discloses application of an SNP (Single Nucleotide Polymorphism) site in predicting the occurrence risk of type 2 diabetic nephropathy, and belongs to the technical field of biological detection. The application finds that the SNP site rs5741812 of the lipopolysaccharide binding protein (LBP) has obvious correlation with the occurrence of the type 2 diabetic nephropathy for the first time, and prompts that the rs5741812 can be used as a marker for predicting or assisting in predicting the occurrence risk of the type 2 diabetic nephropathy, so that the sensitivity and the specificity of predicting the occurrence risk of the type 2 diabetic nephropathy are improved; the method has important significance on clinically predicting early-stage type 2 diabetic nephropathy.

The present disclosure relates to SH3YL1 monoclonal antibodies and compositions comprising the SH3YL1 monoclonal antibodies. The disclosure also relates to isolated nucleic acid molecules encoding the SH3YL1 antibodies, vectors comprising the nucleic acid molecules, and host cells comprising the vectors. Also disclosed are methods of modulating an immune response, methods of treating diabetic nephropathy, and methods of treating non-alcoholic steatosis hepatitis comprising administering the SH3YL1 antibodies. Also disclosed are methods of treating acute kidney injury and methods of treating inflammatory bowel disease comprising administering the SH3YL1 antibodies.

The invention relates to a traditional Chinese medicine composition for treating diabetic nephropathy and a preparation method thereof, and relates to the technical field of traditional Chinese medicine, the traditional Chinese medicine composition for treating diabetic nephropathy comprises the following raw materials by weight: 25-35 parts of prepared rehmannia root, 25-35 parts of dogwood, 15-20 parts of Chinese yam, 15-20 parts of oyster, 7-12 parts of Poria cocos and 7-12 parts of white peony root. According to the present invention, the existing decoction-Jiji decoction has a certain alleviating effect on diabetic nephropathy, and further improvement is performed on the basis of the existing decoction formula, such that after the ossa draconis and the radix aconiti lateralis preparata in the original decoction are removed, the reduced pressure reflux extraction under the specific parameters is adopted so as to achieve the effect of treating diabetic nephropathy; the treatment effect of the obtained traditional Chinese medicine composition on diabetic nephropathy can be remarkably improved, a new means is provided for treatment of patients with diabetic nephropathy, and the application prospect is wide.

The present invention relates to a nanoparticle comprising a nanomaterial and at least a first ligand and a second ligand tethered to the nanoparticle. The present invention also relates to a nanoparticle for use as a medicament or diagnostic agent. The present invention also relates to a nanoparticle for use in a method for preventing or treating a disease selected from the group consisting of diabetic nephropathy, glomerulonephritis, glomerular VEGF A dysregulation, endothelial VEGF A dysregulation, diabetic retinopathy, rheumatoid arthritis, age-related macular degeneration and cancer, such as breast cancer. Furthermore, the present invention relates to a method of preparing a nanoparticle.

The present invention relates to novel compounds and pharmaceutical compositions thereof, and to methods for promoting healthy skin aging, treating skin disorders, treating cardiovascular disorders, treating renal disorders, treating angiogenesis disorders, such as cancer, treating tissue damage, such as non-cardiac tissue damage, treating progressive myocardial infarction, and treating various other disorders, such as complications resulting from diabetes with the compounds and compositions of the invention. Other disorders may include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, skin infections, peripheral vascular disease, stroke, and the like.

The invention discloses compounds of Formula (I), wherein the compounds are used as anti-inflammatory agents, for treatment or prevention of a number of diseases or conditions such as atherosclerosis, auto-immune diseases, psoriasis, multiple sclerosis, transplant rejection, asthma, bacterial infection, rhinovirus infection, brain ischemia, ischemia-reperfusion injury, limb ischemia, acute kidney injury, diabetic nephropathy, sepsis, acute respiratory distress syndrome (ARDS), cancer, osteoarthritis, sepsis-induced kidney injury, liver disease, and septic and cardiogenic shock.

The application relates to a non-invasive diabetic nephropathy grading and prediction method supporting convenient screening, which comprises the following steps: collecting color fundus images and non-invasive clinical characteristics of diabetic patients, pre-processing to obtain a multi-modal data set, and setting annotations of multiple severity degrees of diabetic nephropathy; constructing a deep learning model A1 to obtain a diabetic nephropathy severity prediction probability distribution based on the color fundus images according to the multi-modal data set; constructing a deep learning model A2 to obtain a diabetic nephropathy severity prediction probability distribution based on clinical data according to the multi-modal data set; constructing a fusion model, the fusion model fuses the obtained diabetic nephropathy prediction probabilities through an adaptive weight distribution algorithm, dynamically adjusts the weights according to the prediction results output by each model, calculates a comprehensive diabetic nephropathy severity score, and outputs a final diabetic nephropathy prediction grading result according to the score.

The invention relates to a double fused ring compound inhibitor as well as a preparation method and application thereof. In particular, the present invention relates to a compound represented by general formula (III), a preparation method thereof, a pharmaceutical composition containing the compound, and use thereof in the preparation of drugs for treating chronic kidney disease, renal or cardiac fibrosis, diabetic nephropathy, congestive heart failure, hypertension, primary aldosteronism and Cushing's syndrome.

The invention belongs to the technical field of diabetic nephropathy, and particularly relates to a metabolic risk scoring (MetRS) system for diabetic nephropathy. The diabetic nephropathy metabolism risk scoring system comprises a data acquisition module used for acquiring a metabolic biomarker detection value of a person to be assessed; the risk score calculation module is used for calculating a diabetic nephropathy metabolic risk score of the to-be-evaluated person according to the metabolic biomarker detection value of the to-be-evaluated person; and the risk grade evaluation module is used for evaluating the attack risk of the diabetic nephropathy of the to-be-evaluated person according to the metabolic risk score of the diabetic nephropathy. The method can provide an objective tool for high-risk population identification of diabetic nephropathy, and is of great significance to improvement of diabetic nephropathy management ability and precise prevention and treatment level.

The invention relates to the technical field of functional probiotic screening and application, and particularly provides a strain of lactobacillus plantarum capable of improving pancreas islet dysfunction and diabetic nephropathy and application of the lactobacillus plantarum capable of improving pancreas islet dysfunction and diabetic nephropathy. The preservation number of the plant lactobacillus is CGMCC (China General Microbiological Culture Collection Center) No.31657, and the plant lactobacillus is screened from excrement of healthy infants, has excellent acid resistance and cholate resistance, is high in oxidation resistance and reducing capacity, can effectively control the rise of fasting blood-glucose level of diabetic mice and can enhance the glucose tolerance of the diabetic mice; and the protein also has the capabilities of improving pancreas islet functions and regulating insulin resistance and insulin sensitivity. The strain has a wide application prospect in preparation of drugs for relieving or treating pancreas islet dysfunction and diabetic nephropathy.

The invention relates to the technical field of diabetic nephropathy onset risk, in particular to an onset risk prediction method and system for type 2 diabetic nephropathy, and the method comprises the following steps: screening characteristic factors through multi-factor Logistic regression, and obtaining contribution degree through principal component analysis; information centralization and decentralization feature weights are constructed based on the contribution degree, and the game theory is introduced for fusion to obtain the optimal feature weight; and finally, inputting the weighted features into the attention guidance double-current time sequence static fusion network which is deeply fused with the optimal weight, and outputting an onset risk. According to the method, contributions of core and secondary indexes are balanced through the game theory, and deep association of static and dynamic data is mined by using a double-flow network, so that the prediction accuracy is remarkably improved.